Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism

Drug Metabolism and Disposition

Volumn 44, Issue 3, 2016, Pages 343-351

  Tracy, Timothy S ^a   Chaudhry, Amarjit S ^b   Prasad, Bhagwat ^c   Thummel, Kenneth E ^c   Schuetz, Erin G ^b   Zhong, Xiao Bo ^d   Tien, Yun Chen ^d   Jeong, Hyunyoung ^e   Pan, Xian ^e   Shireman, Laura M ^c   Tay Sontheimer, Jessica ^c   Lin, Yvonne S ^c  

^a University of Kentucky   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; XENOBIOTIC AGENT;

CONFERENCE PAPER; DOWN REGULATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; INTRON; NONHUMAN; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION; ANIMAL; DRUG INACTIVATION; DRUG INTERACTION; GENETIC VARIATION; GENETICS; METABOLISM;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; GENETIC VARIATION; HUMANS; INACTIVATION, METABOLIC; PHENOTYPE; XENOBIOTICS;

EID: 85014519243     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.067900     Document Type: Conference Paper

References (93)

1. Agrawal AK and Shapiro BH (2003) Phenobarbital-imprinted overinduction of adult constituent CYP isoforms. Pharmacology 68:204-215.
2. Agrawal AK and Shapiro BH (2005) Neonatal phenobarbital imprints overexpression of cytochromes P450 with associated increase in tumorigenesis and reduced life span. FASEB J 19: 470-472.
3. Bentayeb K, Batlle R, Sánchez C, Nerín C, and Domeño C (2008) Determination of bile acids in human serum by on-line restricted access material-ultra high-performance liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 869:1-8.
4. Bertilsson L, Dahl ML, Dalén P, and Al-Shurbaji A (2002) Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 53:111-122.
5. Björkhem I, Lövgren-Sandblom A, Leoni V, Meaney S, Brodin L, Salveson L, Winge K, Pålhagen S, and Svenningsson P (2013) Oxysterols and Parkinson's disease: Evidence that levels of 24S-hydroxycholesterol in cerebrospinal fluid correlates with the duration of the disease. Neurosci Lett 555:102-105.
6. Bodin K, Bretillon L, Aden Y, Bertilsson L, Broomé U, Einarsson C, and Diczfalusy U (2001) Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: Evidence for involvement of cytochrome p450 3A4. J Biol Chem 276:38685-38689.
7. Cai SY, He H, Nguyen T, Mennone A, and Boyer JL (2010) Retinoic acid represses CYP7A1 expression in human hepatocytes and HepG2 cells by FXR/RXR-dependent and independent mechanisms. J Lipid Res 51:2265-2274.
8. Cairns W, Smith CA, McLaren AW, and Wolf CR (1996) Characterization of the human cytochrome P4502D6 promoter. A potential role for antagonistic interactions between members of the nuclear receptor family. J Biol Chem 271:25269-25276.
9. Carcillo JA, Adedoyin A, Burckart GJ, Frye RF, Venkataramanan R, Knoll C, Thummel K, Roskos L, Wilson JW, and Sereika S, et al. (2003) Coordinated intrahepatic and extrahepatic regulation of cytochrome p4502D6 in healthy subjects and in patients after liver transplantation. Clin Pharmacol Ther 73:456-467.
10. Chai X, Zeng S, and Xie W (2013) Nuclear receptors PXR and CAR: Implications for drug metabolism regulation, pharmacogenomics and beyond. Expert Opin Drug Metab Toxicol 9: 253-266.
11. Chaudhry AS, Prasad B, Shirasaka Y, Fohner A, Finkelstein D, Fan Y, Wang S, Wu G, Aklillu E, and Sim SC, et al. (2015) The CYP2C19 intron 2 branch point SNP is the ancestral polymorphism contributing to the poor metabolizer phenotype in livers with CYP2C19∗35 and CYP2C19∗2 alleles. Drug Metab Dispos 43:1226-1235.
12. Chaudhry AS, Thirumaran RK, Yasuda K, Yang X, Fan Y, Strom SC, and Schuetz EG (2013) Genetic variation in aldo-keto reductase 1D1 (AKR1D1) affects the expression and activity of multiple cytochrome P450s. Drug Metab Dispos 41:1538-1547.
13. Chen WD, Fu X, Dong B, Wang YD, Shiah S, Moore DD, and Huang W (2012) Neonatal activation of the nuclear receptor CAR results in epigenetic memory and permanent change of drug metabolism in mouse liver. Hepatology 56:1499-1509.
14. Chen Y, Ferguson SS, Negishi M, and Goldstein JA (2004) Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J Pharmacol Exp Ther 308:495-501.
15. Chen YC, Gotzkowsky SK, Nafziger AN, Kulawy RW, Rocci ML, Jr, Bertino JS, Jr, and Kashuba AD (2006) Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity. Br J Clin Pharmacol 62: 187-195.
16. Cheng J, Zhen Y, Miksys S, Beyo-glu D, Krausz KW, Tyndale RF, Yu A, Idle JR, and Gonzalez FJ (2013) Potential role of CYP2D6 in the central nervous system. Xenobiotica 43:973-984.
17. Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, Ritchie MD, Stein CM, Roden DM, and Smith JD, et al. (2008) A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112:1022-1027.
18. Corchero J, Granvil CP, Akiyama TE, Hayhurst GP, Pimprale S, Feigenbaum L, Idle JR, and Gonzalez FJ (2001) The CYP2D6 humanized mouse: Effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. Mol Pharmacol 60: 1260-1267.
19. Croom EL, Stevens JC, Hines RN, Wallace AD, and Hodgson E (2009) Human hepatic CYP2B6 developmental expression: The impact of age and genotype. Biochem Pharmacol 78:184-190.
20. Dahl ML, Johansson I, Palmertz MP, Ingelman-Sundberg M, and Sjöqvist F (1992) Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 51:12-17.
21. Dickmann LJ, Tay S, Senn TD, Zhang H, Visone A, Unadkat JD, Hebert MF, and Isoherranen N (2008) Changes in maternal liver Cyp2c and Cyp2d expression and activity during rat pregnancy. Biochem Pharmacol 75:1677-1687.
22. Diczfalusy U, Kanebratt KP, Bredberg E, Andersson TB, Böttiger Y, and Bertilsson L (2009) 4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and halflife of elimination after induction with rifampicin. Br J Clin Pharmacol 67:38-43.
23. Dutreix C, Lorenzo S, and Wang Y (2014) Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin. Eur J Clin Pharmacol 70:915-920.
24. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, and Leeder JS (2008) The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 83:234-242.
25. Galteau MM and Shamsa F (2003) Urinary 6beta-hydroxycortisol: A validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol 59:713-733.
26. García-Cañaveras JC, Donato MT, Castell JV, and Lahoz A (2012) Targeted profiling of circulating and hepatic bile acids in human, mouse, and rat using a UPLC-MRM-MS-validated method. J Lipid Res 53:2231-2241.
27. Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, De Berardinis V, Martin H, Beaune P, and De Waziers I (1999) Human CYP2B6: Expression, inducibility and catalytic activities. Pharmacogenetics 9:295-306.
28. Gonzalez FJ (2008) Regulation of hepatocyte nuclear factor 4 alpha-mediated transcription. Drug Metab Pharmacokinet 23:2-7.
29. Goodenough AK, Onorato JM, Ouyang Z, Chang S, Rodrigues AD, Kasichayanula S, Huang SP, Turley W, Burrell R, and Bifano M, et al. (2011) Quantification of 4-beta-hydroxycholesterol in human plasma using automated sample preparation and LC-ESI-MS/MS analysis. Chem Res Toxicol 24:1575-1585.
30. Goodwin B, Hodgson E, and Liddle C (1999) The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol 56:1329-1339.
31. Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, Galardi C, Wilson JG, Lewis MC, and Roth ME, et al. (2000) A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 6:517-526.
32. Goodwin B, Moore LB, Stoltz CM, McKee DD, and Kliewer SA (2001) Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol 60:427-431.
33. Gryn SE, Teft WA, and Kim RB (2014) Profound reduction in the tamoxifen active metabolite endoxifen in a patient on phenytoin for epilepsy compared with a CYP2D6 genotype matched cohort. Pharmacogenet Genomics 24:367-369.
34. Guengerich FP (2008) Cytochrome p450 and chemical toxicology. Chem Res Toxicol 21:70-83.
35. Handschin C and Meyer UA (2003) Induction of drug metabolism: The role of nuclear receptors. Pharmacol Rev 55:649-673.
36. Hart SN, Wang S, Nakamoto K, Wesselman C, Li Y, and Zhong XB (2008) Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism. Pharmacogenet Genomics 18:11-24.
37. Hines RN (2007) Ontogeny of human hepatic cytochromes P450. J Biochem Mol Toxicol 21: 169-175.
38. Högstedt S, Lindberg B, Peng DR, Regårdh CG, and Rane A (1985) Pregnancy-induced increase in metoprolol metabolism. Clin Pharmacol Ther 37:688-692.
39. Hou X, Shi J, and Sun H (2014) Gene polymorphism of cytochrome P450 2C19∗2 and clopidogrel resistance reflected by platelet function assays: A meta-analysis. Eur J Clin Pharmacol 70:1041-1047.
40. Hou ZY, Pickle LW, Meyer PS, and Woosley RL (1991) Salivary analysis for determination of dextromethorphan metabolic phenotype. Clin Pharmacol Ther 49:410-419.
41. Hu ZY, Zhao YS, Wu D, and Cheng ZN (2009) Endogenous cortisol 6 beta-hydroxylation clearance is not an accurate probe for overall cytochrome P450 3A phenotyping in humans. Clin Chim Acta 408:92-97.
42. Imamura Y, Tsuruya Y, Damme K, Heer D, Kumagai Y, Maeda K, Murayama N, Okudaira N, Kurihara A, and Izumi T, et al. (2014) 6b-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. Drug Metab Dispos 42:685-694.
43. Kim B, Moon JY, Choi MH, Yang HH, Lee S, Lim KS, Yoon SH, Yu KS, Jang IJ, and Cho JY (2013) Global metabolomics and targeted steroid profiling reveal that rifampin, a strong human PXR activator, alters endogenous urinary steroid markers. J Proteome Res 12:1359-1368.
44. Koh KH, Pan X, Shen HW, Arnold SL, Yu AM, Gonzalez FJ, Isoherranen N, and Jeong H (2014) Altered expression of small heterodimer partner governs cytochrome P450 (CYP) 2D6 induction during pregnancy in CYP2D6-humanized mice. J Biol Chem 289:3105-3113.
45. Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, McCarver DG, and Hines RN (2004) Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther 308:965-974.
46. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, and Hall SD, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391.
47. Lacroix D, Sonnier M, Moncion A, Cheron G, and Cresteil T (1997) Expression of CYP3A in the human liver-evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 247:625-634.
48. Lamba J, Lamba V, Strom S, Venkataramanan R, and Schuetz E (2008) Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab Dispos 36:169-181.
49. Lamba JK, Lin YS, Schuetz EG, and Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271-1294.
50. Lamba V, Ghodke Y, Guan W, and Tracy TS (2014) microRNA-34a is associated with expression of key hepatic transcription factors and cytochromes P450. Biochem Biophys Res Commun 445:404-411.
51. Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML, Fackenthal JD, Rogan PK, Ring B, and Wrighton SA, et al. (2003) Hepatic CYP2B6 expression: Gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 307:906-922.
52. Lamba V, Panetta JC, Strom S, and Schuetz EG (2010) Genetic predictors of interindividual variability in hepatic CYP3A4 expression. J Pharmacol Exp Ther 332:1088-1099.
53. Li T and Chiang JY (2014) Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev 66:948-983.
54. Li Y, Cui Y, Hart SN, Klaassen CD, and Zhong XB (2009) Dynamic patterns of histone methylation are associated with ontogenic expression of the Cyp3a genes during mouse liver maturation. Mol Pharmacol 75:1171-1179.
55. Lin JH and Lu AY (1998) Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35:361-390.
56. Lin JH and Lu AY (2001) Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol 41:535-567.
57. Luo X, Li XM, Hu ZY, and Cheng ZN (2009) Evaluation of CYP3A activity in humans using three different parameters based on endogenous cortisol metabolism. Acta Pharmacol Sin 30: 1323-1329.
58. Madadi P, Amstutz U, Rieder M, Ito S, Fung V, Hwang S, Turgeon J, Michaud V, Koren G, and Carleton BC; CPNDS Clinical Recommendations Group (2013) Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy. J Popul Ther Clin Pharmacol 20:e369-e396.
59. Maloney PR, Parks DJ, Haffner CD, Fivush AM, Chandra G, Plunket KD, Creech KL, Moore LB, Wilson JG, and Lewis MC, et al. (2000) Identification of a chemical tool for the orphan nuclear receptor FXR. J Med Chem 43:2971-2974.
60. De Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, and Goldstein JA (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419-15422.
61. Odom DT, Zizlsperger N, Gordon DB, Bell GW, Rinaldi NJ, Murray HL, Volkert TL, Schreiber J, Rolfe PA, and Gifford DK, et al. (2004) Control of pancreas and liver gene expression by HNF transcription factors. Science 303:1378-1381.
62. Ohno M, Yamaguchi I, Ito T, Saiki K, Yamamoto I, and Azuma J (2000) Circadian variation of the urinary 6beta-hydroxycortisol to cortisol ratio that would reflect hepatic CYP3A activity. Eur J Clin Pharmacol 55:861-865.
63. Pan X and Jeong H (2015) Estrogen-induced cholestasis leads to repressed CYP2D6 expression in CYP2D6-humanized mice. Mol Pharmacol 88:106-112.
64. Pan X, Lee YK, and Jeong H (2015) Farnesoid X receptor agonist represses cytochrome P450 2D6 expression by upregulating small heterodimer partner. Drug Metab Dispos 43:1002-1007.
65. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, and Moore DD, et al. (1999) Bile acids: Natural ligands for an orphan nuclear receptor. Science 284:1365-1368.
66. Peng CC, Templeton I, Thummel KE, Davis C, Kunze KL, and Isoherranen N (2011) Evaluation of 6b-hydroxycortisol, 6b-hydroxycortisone, and a combination of the two as endogenous probes for inhibition of CYP3A4 in vivo. Clin Pharmacol Ther 89: 888-895.
67. Peng L, Yoo B, Gunewardena SS, Lu H, Klaassen CD, and Zhong XB (2012) RNA sequencing reveals dynamic changes of mRNA abundance of cytochromes P450 and their alternative transcripts during mouse liver development. Drug Metab Dispos 40: 1198-1209.
68. Preskorn S, Patroneva A, Silman H, Jiang Q, Isler JA, Burczynski ME, Ahmed S, Paul J, and Nichols AI (2009) Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol 29:39-43.
69. Rahmioglu N, Le Gall G, Heaton J, Kay KL, Smith NW, Colquhoun IJ, Ahmadi KR, and Kemsley EK (2011) Prediction of variability in CYP3A4 induction using a combined 1H NMR metabonomics and targeted UPLC-MS approach. J Proteome Res 10: 2807-2816.
70. Rojas L, Neumann I, Herrero MJ, Boso V, Reig J, Poveda JL, Megias J, Bea S, and Alino SF (2015) Effect of CYP3A5∗3 on kidney transplant recipients treated with tacrolimus: A systematic review and meta-analysis of observational studies. Pharmacogenomics J 15: 38-48.
71. Sachse C, Brockmöller J, Bauer S, and Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences. Am J Hum Genet 60: 284-295.
72. Saitoh A, Sarles E, Capparelli E, Aweeka F, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, and Spector SA (2007) CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS 21: 2191-2199.
73. Shin KH, Choi MH, Lim KS, Yu KS, Jang IJ, and Cho JY (2013) Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance. Clin Pharmacol Ther 94:601-609.
74. Sim SC, Kacevska M, and Ingelman-Sundberg M (2013) Pharmacogenomics of drugmetabolizing enzymes: A recent update on clinical implications and endogenous effects. Pharmacogenomics J 13:1-11.
75. Snider NT, Sikora MJ, Sridar C, Feuerstein TJ, Rae JM, and Hollenberg PF (2008) The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6. J Pharmacol Exp Ther 327:538-545.
76. Sridar C, Snider NT, and Hollenberg PF (2011) Anandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6. Drug Metab Dispos 39:782-788.
77. Stevens JC (2006) New perspectives on the impact of cytochrome P450 3A expression for pediatric pharmacology. Drug Discov Today 11:440-445.
78. Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF, and Rettie AE (1997) Genetic association between sensitivity to warfarin and expression of CYP2C9∗3. Pharmacogenetics 7:361-367.
79. Sueyoshi T, Kawamoto T, Zelko I, Honkakoski P, and Negishi M (1999) The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J Biol Chem 274:6043-6046.
80. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, Whittaker P, Ranganath V, Kumanduri V, and McLaren W, et al. (2009) A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 5:e1000433.
81. Tay-Sontheimer J, Shireman LM, Beyer RP, Senn T, Witten D, Pearce RE, Gaedigk A, Gana Fomban CL, Lutz JD, and Isoherranen N, et al. (2014) Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics. Pharmacogenomics 15:1947-1962.
82. Temesvári M, Kóbori L, Paulik J, Sárváry E, Belic A, and Monostory K (2012) Estimation of drug-metabolizing capacity by cytochrome P450 genotyping and expression. J Pharmacol Exp Ther 341:294-305.
83. Tien YC, Liu K, Pope C, Wang P, Ma X, and Zhong XB (2015) Dose of phenobarbital and age of treatment at early life are two key factors for the persistent induction of cytochrome P450 enzymes in adult mouse liver. Drug Metab Dispos 43:1938-1945.
84. Tracy TS, Venkataramanan R, Glover DD, and Caritis SN; National Institute for Child Health and Human Development Network of Maternal-Fetal-Medicine Units (2005) Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy. Am J Obstet Gynecol 192:633-639.
85. Ukleja A, Scolapio JS, McConnell JP, Spivey JR, Dickson RC, Nguyen JH, and O'Brien PC (2002) Nutritional assessment of serum and hepatic vitamin A levels in patients with cirrhosis. JPEN J Parenter Enteral Nutr 26:184-188.
86. Wadelius M, Darj E, Frenne G, and Rane A (1997) Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther 62:400-407.
87. Wang Z, Lin YS, Zheng XE, Senn T, Hashizume T, Scian M, Dickmann LJ, Nelson SD, Baillie TA, and Hebert MF, et al. (2012) An inducible cytochrome P450 3A4-dependent vitamin D catabolic pathway. Mol Pharmacol 81:498-509.
88. Westlind A, Löfberg L, Tindberg N, Andersson TB, and Ingelman-Sundberg M (1999) Interindividual differences in hepatic expression of CYP3A4: Relationship to genetic polymorphism in the 59-upstream regulatory region. Biochem Biophys Res Commun 259:201-205.
89. Wienkers LC and Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825-833.
90. Yang X, Zhang B, Molony C, Chudin E, Hao K, Zhu J, Gaedigk A, Suver C, Zhong H, and Leeder JS, et al. (2010) Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res 20:1020-1036.
91. Yu AM, Idle JR, Byrd LG, Krausz KW, Küpfer A, and Gonzalez FJ (2003a) Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 13: 173-181.
92. Yu AM, Idle JR, Herraiz T, Küpfer A, and Gonzalez FJ (2003b) Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. Pharmacogenetics 13:307-319.
93. Zanger UM, Fischer J, Raimundo S, Stüven T, Evert BO, Schwab M, and Eichelbaum M (2001) Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11:573-585.